Skip to content
Screener

Prelude Therapeutics PRLD Q2 2026 earnings

Reported August 11, 2026 · Before market open

Revenue$5.7MIn line
EPS-$0.14Beat by $0.06
Revenue estimate$5.7M
EPS estimate-$0.20

Next report

Nov 11, 2026 (in 2 months)
Revenue estimate$35.3M
EPS estimate-$0.16

FAQ

When did Prelude Therapeutics report Q2 2026 earnings?
Prelude Therapeutics (PRLD) reported Q2 2026 earnings on August 11, 2026 before market open.
What were Prelude Therapeutics's Q2 2026 revenue and EPS?
Prelude Therapeutics reported revenue of $5.7M and eps of $-0.14 for Q2 2026.
Did Prelude Therapeutics beat estimates in Q2 2026?
Revenue beat the consensus estimate of $5.7M by -. EPS beat the consensus estimate of $-0.20 by $0.06.
How did Prelude Therapeutics's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 65.9% from $-0.41.
Where can I find Prelude Therapeutics's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-343469) and the 10-Q periodic report (0001193125-26-343475) directly on SEC EDGAR. The filing index links above go to sec.gov.